Latigo reports positive mid-stage trial results for pain drug competing with Vertex's Journavx

Latigo has announced successful mid-stage clinical trial results for its non-opioid pain medication, positioning it as a potential competitor to Vertex Pharmaceuticals' pain drug Journavx in a field historically marked by development failures.